Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments

Abstract Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of Minimal Information for Chemosensitivity Assays (MICHA), accessed via https://micha-protocol.org. Distinguished from existing efforts that are often lacking support from data integration tools, MICHA can automatically extract publicly available information to facilitate the assay annotation including: 1) compounds, 2) samples, 3) reagents and 4) data processing methods. For example, MICHA provides an integrative web server and database to obtain compound annotation including chemical structures, targets and disease indications. In addition, the annotation of cell line samples, assay protocols and literature references can be greatly eased by retrieving manually curated catalogues. Once the annotation is complete, MICHA can export a report that conforms to the FAIR principle (Findable, Accessible, Interoperable and Reusable) of drug screening studies. To consolidate the utility of MICHA, we provide FAIRified protocols from five major cancer drug screening studies as well as six recently conducted COVID-19 studies. With the MICHA web server and database, we envisage a wider adoption of a community-driven effort to improve the open access of drug sensitivity assays.

[1]  S. Ciesek,et al.  A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection , 2021, Scientific data.

[2]  Krystal L. Matthews,et al.  Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo , 2020, Journal of Virology.

[3]  Sam Michael,et al.  An OpenData portal to share COVID-19 drug repurposing data in real time , 2020, bioRxiv.

[4]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[5]  Bruno Coutard,et al.  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication , 2020, Scientific Reports.

[6]  Eva Forssell-Aronsson,et al.  Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens , 2020, Scientific Reports.

[7]  David Shum,et al.  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.

[8]  Seth M Steinberg,et al.  Selumetinib in Children with Inoperable Plexiform Neurofibromas. , 2020, The New England journal of medicine.

[9]  Krister Wennerberg,et al.  Exploration of databases and methods supporting drug repurposing: a comprehensive survey , 2020, Briefings Bioinform..

[10]  Xiangxiang Zeng,et al.  Network-based prediction of drug-target interactions using an arbitrary-order proximity embedded deep forest , 2020, Bioinform..

[11]  T. Aittokallio,et al.  Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer , 2019, npj Systems Biology and Applications.

[12]  Albert-László Barabási,et al.  Network-based prediction of drug combinations , 2019, Nature Communications.

[13]  Andrew R. Leach,et al.  ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..

[14]  Balaguru Ravikumar,et al.  Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles , 2018, Database J. Biol. Databases Curation.

[15]  Juho Rousu,et al.  Learning with multiple pairwise kernels for drug bioactivity prediction , 2018, Bioinform..

[16]  Amos Bairoch,et al.  The Cellosaurus, a Cell-Line Knowledge Resource. , 2018, Journal of biomolecular techniques : JBT.

[17]  Elina Parri,et al.  Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions , 2017, Cell chemical biology.

[18]  Adam J Pawson,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes , 2017, British journal of pharmacology.

[19]  Juho Rousu,et al.  Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors , 2017, PLoS Comput. Biol..

[20]  S. Garattini,et al.  Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[22]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[23]  Scott E. Martin,et al.  Reproducible pharmacogenomic profiling of cancer cell line panels , 2016, Nature.

[24]  Deng Pan,et al.  DGIdb 2.0: mining clinically relevant drug–gene interactions , 2015, Nucleic Acids Res..

[25]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[26]  Michael K. Gilson,et al.  BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology , 2015, Nucleic Acids Res..

[27]  Robert Clarke,et al.  Enhancing reproducibility in cancer drug screening: how do we move forward? , 2014, Cancer research.

[28]  Joshua A. Bittker,et al.  Evolving BioAssay Ontology (BAO): modularization, integration and applications , 2014, J. Biomed. Semant..

[29]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[30]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[31]  Peter Murray-Rust,et al.  Minimum information about a bioactive entity (MIABE) , 2011, Nature Reviews Drug Discovery.

[32]  Nigel W. Hardy,et al.  Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project , 2008, Nature Biotechnology.

[33]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[34]  Krister Wennerberg,et al.  Methods for High-Throughput Drug Combination Screening and Synergy Scoring , 2016, bioRxiv.